Table 1.

Underlying diseases and Aspergillus-associated conditions of patients with an azole-susceptible or -resistant cryptic Aspergillus section Fumigati isolate or an azole-resistant A. fumigatus isolate

Patient	Sex/ age (years)	Comorbidities	Aspergillus-associated clinical conditiona	Specimen	Collection date (dd/mm/yyyy)	Antifungals received prior to collection date	Isolate	Identification	MIC (mg/L)b
									ITC	PSC	VRC
1	M/62	CLL; COPD; community-acquired pneumonia	colonization	BAL	23/05/2000	none	HMR AF 23	A. turcosus	0.25	0.12	0.25
2	M/52	allogeneic stem cell transplantation	non-invasive sinus aspergillosis and nasal septum abscess	nasal sinus abscess	31/07/2000	FLC	HMR AF 39c	A. thermomutatus	2	1	2
3	M/55	probable old TB cavity	chronic cavitary pulmonary aspergillosis	expectorated sputum	18/12/2002	ITC	HMR AF 270	A. fumigatus	2	1	2
4	F/70	lymphoma (cutaneous); COPD	chronic cavitary pulmonary aspergillosis	BAL	26/06/2009	none	HMR AF 832	A. hiratsukae	0.25	0.12	1
5	M/51	COPD; SAHS; AECB	colonization	BAL	14/10/2010	none	HMR AF 1185	A. lentulus	2	0.5	2
6	M/71	congestive heart failure; SAHS; idiopathic haemoptysis	colonization	BAL	08/12/2011	none	HMR AF 1186	A. hiratsukae	0.5	0.25	0.5
7	M/70	diabetes mellitus; COPD; pulmonary Mycobacterium avium disease	colonization	BAL	16/01/2012	none	HMR AF 1038	A. turcosus	2	1	2
8	M/68	COPD; AECB	colonization	expectorated sputum	15/02/2012	none	HMR AF 1041	A. turcosus	0.25	0.12	0.5
9	F/57	kidney transplantation; PCP	colonization	BAL	23/01/2013	none	HMR AF 1120	A. turcosus	0.25	0.06	0.25

Abbreviations: M, male; F, female; SAHS, sleep apnoea/hyponoea syndrome; AECB, acute exacerbation of chronic bronchitis; PCP, Pneumocystis jirovecii pneumonia; BAL, bronchoalveolar lavage; FLC, fluconazole; ITC, itraconazole; PSC, posaconazole; VRC, voriconazole.

^aConditions shown in bold are considered Aspergillus-related diseases.

^bMIC values shown in bold are considered non-WT (indicating resistance).

^cSix other A. thermomutatus isolates were recovered from the same patient.